QIAGEN’s RespiFast RG enhances diagnosis of respiratory infections
European launch for multiplex test that simultaneously detects 22 viral and bacterial pathogens
Hilden, Germany, September 21, 2015 – QIAGEN today announced the European launch of its RespiFast RG Panel, a molecular diagnostic kit that has received CE-IVD marking for the detection and differentiation of 22 pathogens that cause respiratory tract infections in humans. In a single multiplex kit, RespiFast RG Panel provides highly sensitive, accurate results for a broad range of pathogens – 18 viruses and four bacteria – that cause acute upper respiratory tract infection (RTI). The respiratory panel is the first multiplex assay to run on QIAGEN’s flexible QIAsymphony automation platform.
“Clinicians need to have confidence in pinpointing the causes of respiratory tract infections – so they can treat the right pathogen to help each patient. The RespiFast RG Panel provides a highly sensitive tool that detects viral and bacterial infections simultaneously in a single test. Users have full confidence in the reliability of the results, ensured by both extraction and amplification controls,” said Thierry Bernard, QIAGEN’s Senior Vice President, Molecular Diagnostics Business Area. “For the diagnostic laboratory, RespiFast RG Panel offers the flexibility to automate sample preparation on QIAsymphony® SP or to manually extract nucleic acids. Our Rotor-Gene® Q MDx instrument then performs the DNA and RNA detection and delivers reliable results within three and one-half hours.”
Professor Ortwin Adams of the Department of Clinical Virology at the University of Düsseldorf, a co-founder of the RespiVir network in Germany, was one of the first clinical virologists to evaluate the kit. Comparing against a series of in-house developed Real-Time PCR assays, Dr. Adams said: “The RespiFast RG Panel enables the rapid and reliable detection of a wide number of respiratory pathogens within a single assay, including both viral and bacterial causes of respiratory tract infections. RespiFast RG represents an excellent option for effectively managing patients with such respiratory infections."
Respiratory tract infections are the most widespread human diseases, posing significant health threats to children, the elderly and immunocompromised patients. Early diagnosis of RTIs can help patients and healthcare systems by reducing intensive care and the unnecessary prescription of antibiotics.
The RespiFast RG Panel detects among 16 RNA viruses, two DNA viruses and four bacteria. The test panel was developed and manufactured by PathoFinder BV, a privately owned company based in Maastricht, the Netherlands. For additional details on the RespiFast RG Panel, please visit https://www.qiagen.com/de/shop/assay-technologies/complete-assay-kits/human-pathogen-detection/respifast-rg-panel-ce/
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2015, QIAGEN employed approximately 4,400 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).